cysteamine has been researched along with Disease Models, Animal in 89 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 21 (23.60) | 18.7374 |
1990's | 9 (10.11) | 18.2507 |
2000's | 10 (11.24) | 29.6817 |
2010's | 38 (42.70) | 24.3611 |
2020's | 11 (12.36) | 2.80 |
Authors | Studies |
---|---|
Doulgkeris, CM; Eleftheriou, PT; Galanakis, D; Gavalas, AM; Kourounakis, AP; Kourounakis, PN; Rekka, EA; Tsiakitzis, KC; Victoratos, P | 1 |
Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ | 1 |
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
Albersen, M; Besouw, M; Camps, C; Cyr, D; D'Hauwers, K; de Wever, L; Goffredo, BM; Goossens, E; Hamer, R; Janssen, MCH; Kadam, P; Levtchenko, E; Monnens, L; Reda, A; Rega, LR; Spiessens, C; Taranta, A; van den Heuvel, L; Veys, K; Wetzels, A | 1 |
Besouw, M; Reda, A; Veys, K | 1 |
Fang, X; Li, W; Ling, S; Liu, X; Luo, Y; Wang, A; Xu, B; Yao, X; Zhang, S; Zhou, Y; Zong, W | 1 |
Li, Q; Quan, J; Wang, X; Xu, B; Xu, Z | 1 |
Battafarano, G; Bellomo, F; Cairoli, S; Camassei, FD; D'Oria, V; De Leo, E; Del Fattore, A; Emma, F; Goffredo, BM; Pezzullo, M; Polishchuk, E; Polishchuk, R; Raso, R; Rega, LR; Taranta, A | 1 |
Aihara, S; Hirashima, Y; Kitazono, T; Nakano, T; Torisu, K | 1 |
Ahmad, F; Leake, DS; Mohri, Z; Weinberg, PD; Wen, Y | 1 |
D'Souza, RF; Davidson, AJ; Harrison, PT; Hollywood, JA; Holm, TM; Przepiorski, A; Sreebhavan, S; Wolvetang, EJ | 1 |
Ambrogini, P; Bartoccini, F; Cesarini, E; Crinelli, R; De Marchis, F; Di Mambro, T; Diotallevi, A; Fraternale, A; Galluzzi, L; Genovese, DA; Green, K; Luchetti, F; Magnani, M; Manuali, E; Pompa, A; Smietana, M; Zara, C | 1 |
Choi, SY; Choi, YJ; Eum, WS; Han, KH; Kim, DS; Kim, DW; Lee, KW; Lee, LR; Park, J; Park, JK; Shin, MJ; Song, Y; Yeo, EJ; Yeo, HJ | 1 |
Gao, L; Jin, J; Liu, P; Lu, WH; Lv, J; Xie, X; Zhang, H | 1 |
Almaguel, FG; Debinski, W; Herpai, DM; Mintz, A; Pandya, DN; Sattiraju, A; Solingapuram Sai, KK; Wadas, TJ; Xuan, A | 1 |
Cicchetti, F; David, LS; Lamontagne-Proulx, J; Saint-Pierre, M | 1 |
Brinckmann, J; Herold, S; Hitomi, K; Iismaa, SE; Mižíková, I; Morty, RE; Nardiello, C; Pease, RJ; Pfeffer, T; Seeger, W; Silva, DM; Steenbock, H; Surate Solaligue, DE; Tatsukawa, H; Vadász, I | 1 |
Cho, SB; Cho, YJ; Choi, SY; Choi, YJ; Eum, WS; Han, KH; Hwang, JS; Jo, HS; Kim, DS; Kim, DW; Kim, HA; Kim, JA; Lee, CH; Lee, KW; Park, J; Park, JH; Shin, MJ; Yeo, EJ; Yeo, HJ; Yong, JI | 1 |
Krishnamurthy, S; Kumar, AS; Paliwal, P; Patne, SCU; Singh, SP; Tripathi, H | 1 |
Chen, J; Chen, W; Deng, J; He, M; Huang, X; Li, C; Li, Y; Lim, RX; Ma, L; Phan, JB; Wan, F | 1 |
Cho, SH; Cho, SW; Choi, SY; Eum, WS; Hwang, HS; Kim, DW; Ku, SK; Kwon, OS; Lee, SH; Park, J; Yoon, GH | 1 |
Hahm, KB; Han, YM; Kangwan, N; Kim, EH; Kim, JS; Kim, TS; Kim, YJ; Kwon, O; Park, JM | 1 |
Bahrami, NM; Barshop, BA; Duffield, JS; Eddy, AA; Gangoiti, JA; Lopez-Guisa, JM; Okamura, DM; Pasichnyk, K; Ren, S; Williams, JM; Yamaguchi, I | 1 |
Ahluwalia, A; Deng, X; Khomenko, T; Patel, KN; Sandor, Z; Szabo, S; Tarnawski, A | 1 |
Ahn, EH; Cho, SW; Choi, SY; Eom, SA; Eum, WS; Jo, HS; Kim, DS; Kim, DW; Kim, HR; Kim, SM; Park, J; Shin, MJ; Woo, SJ | 1 |
Li, DW; Liu, YL; Sun, BL; Wang, T; Yang, MF; Zhang, JH; Zhang, ZY | 1 |
Choi, SY; Hwang, HS; Jung, YO; Kim, DW; Kim, HA; Park, IY | 1 |
Badrinarayanan, S; Boivin, L; Bousquet, M; Chabrat, A; Charest, J; Cicchetti, F; Cisbani, G; Drouin-Ouellet, J; Gibrat, C; Lagacé, M; Lavallée-Bourget, MH; Lebel, M; Lévesque, M; Saint-Pierre, M | 1 |
Du, F; Fan, D; Ma, L; Tong, C; Wu, Y; Xie, G; Xu, Y; Yu, H | 1 |
Bona, G; Buonpensiero, P; De Gregorio, F; De Rosa, G; De Stefano, D; Di Pasqua, A; Esposito, S; Ferrari, E; Grassia, R; Guido, S; Kroemer, G; Leone, CA; Lusa, S; Maiuri, L; Maiuri, MC; Mehta, A; Raia, V; Salvadori, L; Sana, I; Sepe, A; Stoll, G; Tosco, A | 1 |
De Spiegeleer, B; Fortin, A; Gauthier, S; Gros, P; Hawari, J; Moradin, N; Stevenson, MM; Tam, M; Torre, S; Vandercruyssen, K | 1 |
Bodas, M; Chandramani-Shivalingappa, P; Hole, R; Van Westphal, C; Vij, N | 1 |
Choi, SY; Hwang, HS; Kim, HA; Park, IY | 1 |
Amagai, M; Ishikawa, H; Jin, L; Kameyama, K; Kawachi, S; Kitagawa, Y; Kitajima, M; Kubota, T; Kumai, K; Nagao, K; Nakamura, T; Saikawa, Y; Sano, K; Shinoda, M; Tanabe, M; Wada, N; Wakabayashi, G; Yoshida, M | 1 |
Chan, P; Sun, L; Wang, C; Wu, Y; Xu, S; Zhou, M | 1 |
Choi, SE; Choi, YW; Eum, JY; Kang, KH; Kang, MH; Kang, MJ; Lee, MW; Oh, CH; Park, KH; Park, SH | 1 |
Jouyban, A; Karimi, I; Saghaei, F; Samini, M | 1 |
Cicchetti, F; Gibrat, C | 1 |
Asad, M; Asres, K; Engidawork, E; Melese, E | 1 |
Ahn, EH; Choi, SY; Eum, WS; Jeong, HJ; Kang, HW; Kim, DW; Kim, MJ; Kim, SY; Kim, TY; Kim, YN; Kwon, HJ; Kwon, SW; Lee, KS; Park, J; Shin, MJ; Sohn, EJ | 1 |
Gros, P; Min-Oo, G | 1 |
Chen, L; Deng, X; Folkman, J; Khomenko, T; Osapay, K; Sandor, Z; Shiloach, J; Szabo, S; Tolstanova, G; Xiong, X | 1 |
Geetha, A; Saranya, P | 1 |
Arumugam, G; Karthikeyan, NS; Panneerselvam, S | 1 |
Flynn, KJ; Jester, JV; Nien, CJ; Simpson, JL | 1 |
Cho, SY; Jeong, EM; Jeong, J; Kim, HJ; Kim, IG; Kim, MK; Lee, HJ; Lee, JH; Lee, SM; Lim, J; Shin, DM; Wee, WR | 1 |
Choi, KS; Hahm, KB; Hong, H; Kim, EH; Kim, JH; Lee, JS; Ock, CY | 1 |
Fujisawa, T; Gahl, WA; Joshi, BH; Patel, PS; Puri, RK; Rubin, B; Suzuki, A | 1 |
Aparecida Severi, J; Bonamin, F; Cássia Santos, R; Hiruma-Lima, CA; Rodrigues Orsi, P; Stasi, LC; Vilegas, W | 1 |
Cho, SW; Cho, YS; Choi, SY; Eom, SA; Eum, WS; Hwang, HS; Kim, DS; Kim, DW; Kim, YN; Lee, SH; Park, J; Sohn, EJ; Yoon, GH | 1 |
Das, PK; Kar, D; Pillai, S; Pradhan, D; Sahoo, S | 1 |
Hobsley, M; Paul Jayaraj, A; Tovey, FI | 1 |
Tsai, SJ | 1 |
Casabianca, A; Chiarantini, L; Cinatl, J; Clayette, P; Fraternale, A; Magnani, M; Oiry, J; Orlandi, C; Paoletti, MF; Schiavano, GF; Vogel, JU | 1 |
Athaydes, GA; Dornelles, PK; Feksa, LR; Fleck, RM; Rech, VC; Rodrigues-Junior, V; Wannmacher, CM | 1 |
Gallagher, GT; Horner, HC; Kovacs, K; McComb, DJ; Schwedes, U; Szabo, S; Usadel, KH | 1 |
Fisher, EA; Gahl, WA | 1 |
Bálint, GA; Náfrádi, J; Varró, V | 1 |
Hüttner, I; Kovacs, K; McComb, DJ; Szabo, S | 1 |
Wattenberg, LW | 1 |
Hosoda, S; Ikedo, H; Saito, T | 1 |
Matsuoka, N; Yamaguchi, I; Yamazaki, M | 1 |
Duvnjak, M; Grabarevic, Z; Jagic, V; Mise, S; Petek, M; Rotkvic, I; Rucman, R; Seiwerth, S; Sikiric, P; Turkovic, B | 1 |
Harding, RK; Krantis, A; McKay, AE; Morris, GP | 1 |
Desai, JK; Goyal, RK; Parmar, NS | 1 |
Ergun, E; Gürbüz, I; Yeşilada, E | 1 |
Dodig, M; Duvnjak, M; Ivankovic, D; Rotkvic, I; Simicevic, VN; Troskot, B | 1 |
Cole, L; Congdon, NT; Duncan, DT; Fisher, DT; Hazelwood, DT; McNaughton, C; Pham, T; Rieger, KT; Sanchez, AT; Urist, JT; Vitale, ST; West, ST | 1 |
Loiseau, PM; Lubert, P; Wolf, JG | 1 |
Cheon, HG; Lee, DH; Lee, SS; Lim, H | 1 |
Abraham, BK; Asad, M; Koumaravelou, K; Ramaswamy, S; Shewade, DG; Vasu, S | 1 |
Haith, LR; Reynolds, ES; Szabo, S | 1 |
Szabo, S | 1 |
Japundzic, I; Levi, E; Rakic-Stojiljkovic, L | 1 |
Millard, WJ; Romano, TM | 1 |
Davis, KL; Haroutunian, V; Santucci, AC | 1 |
Iarygin, KN; Krivosheev, OG; Moskovkin, GN; Polonskiĭ, VM; Vinogradov, VA | 1 |
Azcarraga, F; Bermúdez, JD; Calvo, MA; Esplugues, J; Lloris, JM; Martí, E; Narbona, B | 1 |
Pihan, G; Szabo, S | 1 |
Pfeiffer, CJ; Pfeiffer, DC; Szabo, S | 1 |
Cahill, MC; Gallagher, GT; Szabo, S | 1 |
Miura, Y; Nagamatsu, Y; Ohe, K; Taoka, Y; Yagita, M | 1 |
Kuwahara, Y; Okabe, S; Tanaka, H | 1 |
Kamogawa, A; Kumasaka, M; Ohta, S; Shinoda, M; Tatsugi, A | 1 |
Gallagher, GT; Pihan, G; Szabo, S | 1 |
Kirkegaard, P; Olsen, PS; Poulsen, SS | 1 |
Andreev, VI; Blagovidov, DF; Kaem, RI; Mirkhodzhaev, IA | 1 |
Badalamenti, JN; Lancaster, C; Nezamis, JE; Robert, A | 1 |
Selye, H; Szabo, S | 1 |
5 review(s) available for cysteamine and Disease Models, Animal
Article | Year |
---|---|
Fertility in Cystinosis.
Topics: Animals; Biomarkers; Cysteamine; Cystinosis; Disease Models, Animal; Fertility; Humans; Models, Biological | 2021 |
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Topics: Animals; Cystamine; Cysteamine; Disease Models, Animal; Enzyme Inhibitors; Humans; Huntington Disease; Mice; Mice, Transgenic; Molecular Targeted Therapy; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Radiation-Protective Agents | 2011 |
Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria.
Topics: Amidohydrolases; Animals; Artemisinins; Cysteamine; Disease Models, Animal; Drug Therapy, Combination; GPI-Linked Proteins; Humans; Malaria; Mice; Plasmodium | 2011 |
Inhibition of chemical carcinogenesis by antioxidants.
Topics: Animals; Antioxidants; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Carcinogens; Cysteamine; Disease Models, Animal; Disulfiram; Ethoxyquin; Selenium | 1980 |
Development and significance of cysteamine and propionitrile models of duodenal ulcer.
Topics: Animals; Circadian Rhythm; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Gastric Acid; Gastrointestinal Motility; Mice; Nitriles; Rats | 1987 |
1 trial(s) available for cysteamine and Disease Models, Animal
Article | Year |
---|---|
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.
Topics: Adolescent; Animals; Autophagy; Biomarkers; Catechin; Child; Cysteamine; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Models, Animal; Drug Therapy, Combination; Homozygote; Humans; Interleukin-8; Lung; Mice; Mice, Knockout; Mutation; Sputum; Tumor Necrosis Factor-alpha | 2016 |
83 other study(ies) available for cysteamine and Disease Models, Animal
Article | Year |
---|---|
Synthesis and pharmacochemical study of novel polyfunctional molecules combining anti-inflammatory, antioxidant, and hypocholesterolemic properties.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antioxidants; Arthritis; Cholesterol; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Female; Inflammation; Pipecolic Acids; Proline; Rats; Rats, Inbred F344; Structure-Activity Relationship; Triglycerides | 2006 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Human and animal fertility studies in cystinosis reveal signs of obstructive azoospermia, an altered blood-testis barrier and a subtherapeutic effect of cysteamine in testis.
Topics: Adult; Animals; Azoospermia; Blood-Testis Barrier; Cysteamine; Cystine Depleting Agents; Cystinosis; Disease Models, Animal; Extracellular Matrix Proteins; Humans; Infertility, Male; Male; Mice; Mice, Inbred C57BL; Middle Aged; Neoplasm Proteins; Retrospective Studies; Testis; Young Adult; Zonula Occludens-1 Protein | 2021 |
Transglutaminase 3 Attenuates Skin Inflammation in Psoriasis by Inhibiting NF-κB Activation through Phosphorylated STAT3-TET3 Signaling.
Topics: Animals; Cysteamine; Cytokines; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; RNA, Small Interfering; Skin; STAT3 Transcription Factor; Transglutaminases | 2022 |
N-cystaminylbiguanide MC001 prevents neuron cell death and alleviates motor deficits in the MPTP-model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Death; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Glutamate-Cysteine Ligase; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Substantia Nigra | 2022 |
Genistein improves renal disease in a mouse model of nephropathic cystinosis: a comparison study with cysteamine.
Topics: Animals; Cysteamine; Cystine; Cystinosis; Disease Models, Animal; Female; Genistein; Kidney; Kidney Diseases; Mice | 2023 |
Acrolein produced during acute kidney injury promotes tubular cell death.
Topics: Acrolein; Acute Kidney Injury; Animals; Cell Death; Cysteamine; Disease Models, Animal; Humans; Hypoxia; Ischemia; Kidney; Mice; Oxygen; Polyamines; Reperfusion Injury; RNA, Messenger | 2023 |
Cysteamine inhibits lysosomal oxidation of low density lipoprotein in human macrophages and reduces atherosclerosis in mice.
Topics: Animals; Antioxidants; Aorta; Aortic Diseases; Atherosclerosis; Cysteamine; Disease Models, Animal; Female; Foam Cells; Humans; Hydrogen-Ion Concentration; Lipoproteins, LDL; Lysosomes; Mice, Knockout; Oxidation-Reduction; Plaque, Atherosclerotic; Receptors, LDL; Sphingomyelin Phosphodiesterase; THP-1 Cells | 2019 |
Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
Topics: Amino Acid Transport Systems, Neutral; Animals; Autophagy; Cell Line; CRISPR-Cas Systems; Cysteamine; Cystine; Cystinosis; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Everolimus; Gene Editing; Heterografts; Humans; Induced Pluripotent Stem Cells; Lysosomes; Mice; Mice, SCID; Organoids; Phenotype; TOR Serine-Threonine Kinases | 2020 |
I-152, a supplier of N-acetyl-cysteine and cysteamine, inhibits immunoglobulin secretion and plasma cell maturation in LP-BM5 murine leukemia retrovirus-infected mice by affecting the unfolded protein response.
Topics: Acetylcysteine; Animals; Antiviral Agents; Cysteamine; Disease Models, Animal; Female; Immunoglobulins; Injections, Intraperitoneal; Leukemia, Experimental; Mice; Mice, Inbred C57BL; Plasma Cells; Protein Unfolding; Retroviridae Infections; Tumor Virus Infections; Unfolded Protein Response | 2020 |
PEP-1-GLRX1 Reduces Dopaminergic Neuronal Cell Loss by Modulating MAPK and Apoptosis Signaling in Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell Line; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Gene Expression Regulation; Glutaredoxins; Humans; Male; MAP Kinase Signaling System; Mice; Parkinson Disease; Peptides; Substantia Nigra | 2021 |
Propensity of IgA to self-aggregate via tailpiece cysteine-471 and treatment of IgA nephropathy using cysteamine.
Topics: Animals; Cysteamine; Cysteine; Cystine Depleting Agents; Disease Models, Animal; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Immunoglobulin J-Chains; Kidney Glomerulus; Mice; Protein Aggregation, Pathological; Rats | 2021 |
IL13RA2 targeted alpha particle therapy against glioblastomas.
Topics: Actinium; Alpha Particles; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Copper Radioisotopes; Cysteamine; Disease Models, Animal; DNA Breaks, Double-Stranded; Gene Expression; Glioblastoma; Humans; Interleukin-13 Receptor alpha2 Subunit; Isotope Labeling; Male; Mice; Peptides; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2017 |
The effects of cysteamine in a mouse model of levodopa-induced dyskinesias.
Topics: Animals; Cysteamine; Cystine Depleting Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Mice | 2018 |
Targeting transglutaminase 2 partially restores extracellular matrix structure but not alveolar architecture in experimental bronchopulmonary dysplasia.
Topics: Animals; Bronchopulmonary Dysplasia; Collagen; Cysteamine; Dipeptides; Disease Models, Animal; Extracellular Matrix; Female; Gene Expression Regulation, Developmental; Gene Expression Regulation, Enzymologic; GTP-Binding Proteins; Hyperoxia; Lung; Mice, Inbred C57BL; Mice, Knockout; Molecular Targeted Therapy; Protein Glutamine gamma Glutamyltransferase 2; Pulmonary Alveoli; Transglutaminases | 2018 |
PEP-1-PEA15 suppresses inflammatory responses by regulation of MAPK in macrophages and animal models.
Topics: Animals; Apoptosis Regulatory Proteins; Cysteamine; Cytokines; Disease Models, Animal; DNA Fragmentation; Edema; Extracellular Signal-Regulated MAP Kinases; Humans; Inflammation; Inflammation Mediators; Intracellular Signaling Peptides and Proteins; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred ICR; Peptides; Phosphoproteins; RAW 264.7 Cells; Reactive Oxygen Species; Signal Transduction; Tetradecanoylphorbol Acetate | 2018 |
Pharmacological application of barium containing bioactive glass in gastro-duodenal ulcers.
Topics: Animals; Barium; Barium Compounds; Ceramics; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Male; Oxides; Rats; Rats, Wistar; Stomach Ulcer | 2018 |
Investigation of copper-cysteamine nanoparticles as a new photosensitizer for anti-hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Copper; Cysteamine; Disease Models, Animal; Dose-Response Relationship, Drug; Exosomes; Humans; Liver Neoplasms; Metal Nanoparticles; Mice; Photosensitizing Agents; Singlet Oxygen; Solubility; Ultraviolet Rays; Xenograft Model Antitumor Assays | 2019 |
Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model.
Topics: Administration, Topical; Animals; Botulinum Toxins, Type A; Cell Line; Conjunctiva; Cornea; Cysteamine; Disease Models, Animal; Dry Eye Syndromes; Immunohistochemistry; Interleukin-1beta; Macrophage Inflammatory Proteins; Mice; Peptides; Recombinant Fusion Proteins; Tacrolimus Binding Proteins; Transduction, Genetic; Tumor Necrosis Factor-alpha | 2013 |
Anti-inflammatory and carbonic anhydrase restoring actions of yam powder (Dioscorea spp) contribute to the prevention of cysteamine-induced duodenal ulcer in a rat model.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents; Anti-Ulcer Agents; Carbonic Anhydrases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cysteamine; Cytokines; Dioscorea; Disease Models, Animal; Duodenal Ulcer; Inflammation Mediators; Male; Nitric Oxide Synthase Type II; Pantoprazole; Phytotherapy; Plant Preparations; Plant Tubers; Powders; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2013 |
Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD.
Topics: Actins; Animals; Antioxidants; Cell Differentiation; Cell Line; Cell Proliferation; Cysteamine; Disease Models, Animal; Extracellular Matrix Proteins; Fibrosis; GTP-Binding Proteins; Macrophages; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Oxidative Stress; Protein Glutamine gamma Glutamyltransferase 2; Rats; Renal Insufficiency, Chronic; RNA, Messenger; Transglutaminases; Ureteral Obstruction | 2014 |
STAT3 and importins are novel mediators of early molecular and cellular responses in experimental duodenal ulceration.
Topics: Active Transport, Cell Nucleus; alpha Karyopherins; Animals; Apoptosis; beta Karyopherins; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Early Growth Response Protein 1; Epirizole; Female; Gene Expression Regulation; Mice; Mice, Knockout; Oligodeoxyribonucleotides; Phosphorylation; Rats; Rats, Sprague-Dawley; Signal Transduction; STAT3 Transcription Factor; Time Factors; Tyrosine | 2014 |
PEP-1-PEA-15 protects against toxin-induced neuronal damage in a mouse model of Parkinson's disease.
Topics: Animals; Apoptosis Regulatory Proteins; Cysteamine; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Parkinson Disease; Peptides; Phosphoproteins; Reactive Oxygen Species; Recombinant Fusion Proteins; Transduction, Genetic | 2014 |
Cysteamine alleviates early brain injury via reducing oxidative stress and apoptosis in a rat experimental subarachnoid hemorrhage model.
Topics: Animals; Apoptosis; Behavior, Animal; Blood-Brain Barrier; Brain Edema; Brain Injuries; Brain-Derived Neurotrophic Factor; Caspase 3; Cerebral Cortex; Cysteamine; Disease Models, Animal; Fluorescent Antibody Technique; In Situ Nick-End Labeling; Male; Oxidative Stress; Permeability; Rats, Sprague-Dawley; Reactive Oxygen Species; Subarachnoid Hemorrhage | 2015 |
PEP-1-FK506BP12 inhibits matrix metalloproteinase expression in human articular chondrocytes and in a mouse carrageenan-induced arthritis model.
Topics: Animals; Arthritis; Carrageenan; Cartilage, Articular; Cells, Cultured; Chondrocytes; Cysteamine; Disease Models, Animal; Edema; Humans; Interleukin-1beta; Matrix Metalloproteinase 13; Mice; Mitogen-Activated Protein Kinases; NF-kappa B; Peptides; Recombinant Fusion Proteins; Tacrolimus Binding Protein 1A; Transduction, Genetic | 2015 |
Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Astrocytes; Cell Line; Cells, Cultured; Corpus Striatum; Cystamine; Cysteamine; Disease Models, Animal; Dopaminergic Neurons; Indans; Lipopolysaccharides; Male; Mice, Inbred C57BL; Neurites; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders | 2015 |
PEP-1-MsrA ameliorates inflammation and reduces atherosclerosis in apolipoprotein E deficient mice.
Topics: Animals; Apolipoproteins E; Apoptosis; Aryldialkylphosphatase; Atherosclerosis; Cell Line; Cysteamine; Disease Models, Animal; Escherichia coli; HeLa Cells; Humans; Inflammation; Liver; Macrophages; Male; Methionine Sulfoxide Reductases; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidation-Reduction; Oxidative Stress; Peptides; Protein Structure, Tertiary; Reactive Oxygen Species; Recombinant Fusion Proteins; Superoxide Dismutase | 2015 |
Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria.
Topics: Animals; Antimalarials; Artemisinins; Cell Survival; Cysteamine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Malaria; Malaria, Cerebral; Mice; Plasmodium berghei; Plasmodium chabaudi; Survival Analysis; Treatment Outcome | 2016 |
Cigarette smoke-induced autophagy impairment accelerates lung aging, COPD-emphysema exacerbations and pathogenesis.
Topics: Animals; Autophagy; Case-Control Studies; Cell Line; Cellular Senescence; Cigarette Smoking; Cysteamine; Cytokines; Disease Models, Animal; Disease Progression; Epithelial Cells; Humans; Inclusion Bodies; Inflammation Mediators; Lung; Mice, Inbred C57BL; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Sequestosome-1 Protein; Severity of Illness Index; Smoke; Ubiquitination | 2018 |
PEP-1-GRX-1 Modulates Matrix Metalloproteinase-13 and Nitric Oxide Expression of Human Articular Chondrocytes.
Topics: Animals; Carrageenan; Cartilage, Articular; Cells, Cultured; Cysteamine; Disease Models, Animal; Down-Regulation; Edema; Glutaredoxins; Humans; Immunohistochemistry; Interleukin-1beta; Lipopolysaccharides; Male; Matrix Metalloproteinase 13; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; Nitric Oxide; Peptides; Recombinant Fusion Proteins; Signal Transduction | 2017 |
Candida albicans infection delays duodenal ulcer healing in cysteamine-induced duodenal ulcers in rats.
Topics: Animals; Candida albicans; Candidiasis; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Male; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Time Factors; Vascular Endothelial Growth Factor A; Wound Healing | 2008 |
Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cysteamine; Disease Models, Animal; Dopamine; Glutathione; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Reactive Oxygen Species; Substantia Nigra; Treatment Outcome | 2010 |
Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cysteamine; Dermatitis, Atopic; Disease Models, Animal; Drug Carriers; Elasticity; Excipients; Glucosides; Liposomes; Male; Mice; Mice, Inbred ICR; Peptides; Permeability; Quercetin; Skin Absorption | 2010 |
Effects of captopril on the cysteamine-induced duodenal ulcer in the rat.
Topics: Animals; Biomarkers; Captopril; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Free Radical Scavengers; Glutathione Peroxidase; Male; Malondialdehyde; Oxidative Stress; Radiation-Protective Agents; Rats; Rats, Wistar; Superoxide Dismutase | 2012 |
Evaluation of the antipeptic ulcer activity of the leaf extract of Plantago lanceolata L. in rodents.
Topics: Acetic Acid; Animals; Anti-Ulcer Agents; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Ethiopia; Female; Male; Mice; Peptic Ulcer; Plant Extracts; Plant Leaves; Plantago; Rats; Rats, Sprague-Dawley | 2011 |
Transduced PEP-1-FK506BP ameliorates atopic dermatitis in NC/Nga mice.
Topics: Animals; Cysteamine; Dermatitis, Atopic; Disease Models, Animal; Immunoglobulin E; Interferon-gamma; MAP Kinase Signaling System; Mice; NF-kappa B; Peptides; Recombinant Fusion Proteins; Tacrolimus Binding Proteins; Tumor Necrosis Factor-alpha | 2011 |
Inappropriate angiogenic response as a novel mechanism of duodenal ulceration and impaired healing.
Topics: Angiostatins; Animals; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Endostatins; Enzyme Inhibitors; Female; Intestinal Mucosa; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neovascularization, Pathologic; Nitriles; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Vascular Endothelial Growth Factor A; Wound Healing | 2011 |
Antiulcer activity of Andrographis paniculata (Burm.f.) wall. against cysteamine-induced duodenal ulcer in rats.
Topics: Andrographis; Animals; Anti-Ulcer Agents; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Intestinal Mucosa; Male; Medicine, Ayurvedic; Plant Components, Aerial; Plant Extracts; Rats; Rats, Wistar | 2011 |
Effect of andrographolide on cysteamine-induced duodenal ulcer in rats.
Topics: Alkaline Phosphatase; alpha-Glucosidases; Andrographis; Animals; Anti-Ulcer Agents; Cysteamine; Disease Models, Animal; Diterpenes; Duodenal Ulcer; Duodenum; Glutathione; Intestinal Mucosa; Male; Microvilli; Plant Extracts; Plant Leaves; Rats; Rats, Wistar; Sucrase | 2011 |
Evaluation of topical cysteamine therapy in the CTNS(-/-) knockout mouse using in vivo confocal microscopy.
Topics: Administration, Ophthalmic; Amino Acid Transport Systems, Neutral; Animals; Cornea; Crystallization; Cysteamine; Cystine; Cystinosis; Disease Models, Animal; Humans; Mice; Mice, Knockout; Microscopy, Confocal; Ophthalmic Solutions; Treatment Outcome; Visual Acuity | 2011 |
Cysteamine prevents the development of lens opacity in a rat model of selenite-induced cataract.
Topics: Animals; Animals, Newborn; Cataract; Cell Line; Cysteamine; Disease Models, Animal; Enzyme Activation; Epithelial Cells; Female; Glutathione; GTP-Binding Proteins; Humans; Lens, Crystalline; Male; Protein Glutamine gamma Glutamyltransferase 2; Radiation-Protective Agents; Rats; Rats, Sprague-Dawley; Sodium Selenite; Transglutaminases | 2012 |
Attenuation of cysteamine-induced duodenal ulcer with Cochinchina momordica seed extract through inhibiting cytoplasmic phospholipase A2/5-lipoxygenase and activating γ-glutamylcysteine synthetase.
Topics: Animals; Anti-Ulcer Agents; Antioxidants; Arachidonate 5-Lipoxygenase; Cell Line; Cyclooxygenase 2; Cysteamine; Disease Models, Animal; Dose-Response Relationship, Drug; Duodenal Ulcer; Duodenum; Enzyme Activation; Enzyme Activators; Gastrins; Glutamate-Cysteine Ligase; Glutathione; Inflammation Mediators; Intestinal Mucosa; Lipoxygenase Inhibitors; Male; Momordica; Oxidation-Reduction; Oxidative Stress; Phospholipases A2, Cytosolic; Plant Extracts; Rats; Rats, Sprague-Dawley; Seeds; Time Factors | 2012 |
Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cysteamine; Disease Models, Animal; Enzyme Inhibitors; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2012 |
Hymenaea stigonocarpa Mart. ex Hayne: a Brazilian medicinal plant with gastric and duodenal anti-ulcer and antidiarrheal effects in experimental rodent models.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antidiarrheals; Brazil; Castor Oil; Cysteamine; Diarrhea; Disease Models, Animal; Duodenal Ulcer; Ethanol; Female; Flavonoids; Fruit; Gastric Mucosa; Glutathione; Hymenaea; Intestinal Mucosa; Male; Mice; Mice, Inbred Strains; Nitric Oxide; Peroxidase; Phenols; Phytotherapy; Plant Bark; Plant Extracts; Plant Stems; Plants, Medicinal; Rats; Rats, Wistar; Reperfusion Injury; Stomach Ulcer; Tannins | 2012 |
PEP-1-p18 prevents neuronal cell death by inhibiting oxidative stress and Bax expression.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line; Cysteamine; Disease Models, Animal; DNA Fragmentation; Dopaminergic Neurons; Genetic Vectors; Humans; Mice; MPTP Poisoning; Oxidative Stress; Parkinson Disease; Peptides | 2012 |
Pharmacological efficacy of argemone mexicana plant extract, against cysteamine-induced duodenal ulceration in rats.
Topics: Animals; Argemone; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Male; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Treatment Outcome | 2011 |
Duodenal ulcer prevalence: research into the nature of possible protective dietary lipids.
Topics: Animals; Anti-Ulcer Agents; Cysteamine; Dietary Fats; Disease Models, Animal; Dolichos; Duodenal Ulcer; Duodenum; Ethanol; Female; Phytotherapy; Plant Extracts; Prevalence; Rats; Rats, Wistar | 2003 |
Cysteamine-related agents could be potential antidepressants through increasing central BDNF levels.
Topics: Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Cysteamine; Depressive Disorder, Major; Disease Models, Animal; Humans; Mice | 2006 |
Inhibition of murine AIDS by pro-glutathione (GSH) molecules.
Topics: Acetylcysteine; Animals; Anti-HIV Agents; Cell Proliferation; Cysteamine; Disease Models, Animal; DNA, Viral; Female; Glutathione; Hypergammaglobulinemia; Immunoglobulin G; Leukemia Virus, Murine; Lymph Nodes; Lymphocytes; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Organ Size; Polymerase Chain Reaction; Prodrugs; Spleen | 2008 |
Cysteamine prevents inhibition of thiol-containing enzymes caused by cystine or cystine dimethylester loading in rat brain cortex.
Topics: Animals; Antioxidants; Cerebral Cortex; Creatine Kinase; Cysteamine; Cystine; Cystinosis; Disease Models, Animal; Enzyme Inhibitors; Lysosomes; Oxidation-Reduction; Oxidative Stress; Pyruvate Kinase; Rats; Rats, Wistar; Sulfhydryl Compounds | 2008 |
Cysteamine-induced adrenocortical necrosis in rats.
Topics: Adrenal Cortex Diseases; Adrenal Glands; Adrenal Medulla; Animals; Cysteamine; Disease Models, Animal; Dopamine; Female; Hypophysectomy; Microscopy, Electron; Necrosis; Norepinephrine; Rats; Rats, Inbred Strains; Somatostatin | 1981 |
Cysteamine in treatment of type III hyperlipidaemia?
Topics: Animals; Cysteamine; Disease Models, Animal; Humans; Hyperlipoproteinemia Type III; Lipoproteins, VLDL; Receptors, Cell Surface; Receptors, Lipoprotein | 1982 |
The effect of naloxone in different gastroduodenal ulcer models.
Topics: Animals; Cysteamine; Disease Models, Animal; Female; Gastric Mucosa; Indomethacin; Male; Naloxone; Peptic Ulcer; Rats; Rats, Inbred Strains; Receptors, Opioid; Sex Factors; Stress, Physiological | 1983 |
Adrenocortical hemorrhagic necrosis: the role of catecholamines and retrograde medullary-cell embolism.
Topics: Acrylonitrile; Adrenal Cortex Diseases; Adrenal Medulla; Animals; Catecholamines; Cysteamine; Disease Models, Animal; Embolism; Female; Hemorrhage; Humans; Necrosis; Pyrazoles; Rats; Rats, Inbred Strains | 1981 |
Praomys (Mastomys) natalensis: animal model for study of histamine-induced duodenal ulcers.
Topics: Animals; Cimetidine; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Female; Gastrins; Guinea Pigs; Histamine; Male; Mice; Mice, Inbred DBA; Pentagastrin; Rats; Rodentia; Species Specificity; Tetragastrin | 1981 |
Changes in brain somatostatin in memory-deficient rats: comparison with cholinergic markers.
Topics: Aging; Animals; Avoidance Learning; Biomarkers; Brain; Cerebral Cortex; Choline O-Acetyltransferase; Cognition; Corpus Striatum; Cysteamine; Dementia; Disease Models, Animal; Hippocampus; Male; Maze Learning; Memory Disorders; Raphe Nuclei; Rats; Rats, Inbred F344; Reference Values; Somatostatin | 1995 |
The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides.
Topics: Amino Acid Sequence; Animals; Cysteamine; Disease Models, Animal; Dopamine Agents; Duodenal Ulcer; Ethanol; Female; Gastrointestinal Hormones; Histamine H2 Antagonists; Male; Molecular Sequence Data; Peptide Fragments; Proteins; Rats; Rats, Wistar; Stomach Ulcer; Stress, Physiological | 1994 |
Effects of compound U74500A in animal models of gastric and duodenal ulceration.
Topics: Analysis of Variance; Animals; Anti-Ulcer Agents; Cysteamine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Duodenal Ulcer; Ethanol; Female; gamma-Aminobutyric Acid; In Vitro Techniques; Intestine, Small; Male; Pregnatrienes; Rats; Rats, Sprague-Dawley; Stomach Ulcer | 1993 |
Gastric and duodenal anti-ulcer activity of SKF 38393, a dopamine D1-receptor agonist in rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Anti-Ulcer Agents; Cysteamine; Disease Models, Animal; Dopamine Agonists; Duodenal Ulcer; Female; Immersion; Male; Rats; Rats, Wistar; Receptors, Dopamine D1; Stomach Ulcer | 1995 |
Effects of Cistus laurifolius L. flowers on gastric and duodenal lesions.
Topics: Animals; Anti-Ulcer Agents; Cysteamine; Disease Models, Animal; Ethanol; Female; Gastric Acid; Indomethacin; Male; Mice; Organ Size; Peptic Ulcer; Plant Extracts; Rats; Rats, Wistar; Serotonin | 1997 |
The protective effect of zinc sulphate pretreatment against duodenal ulcers in the rat.
Topics: Administration, Oral; Animals; Cysteamine; Disease Models, Animal; Dose-Response Relationship, Drug; Duodenal Ulcer; Duodenum; Female; Injections, Intraperitoneal; Intestinal Absorption; Rats; Rats, Wistar; Spectrophotometry, Atomic; Zinc; Zinc Sulfate | 1997 |
The effect of pantethine and ultraviolet-B radiation on the development of lenticular opacity in the emory mouse.
Topics: Animals; Cataract; Cysteamine; Disease Models, Animal; Disease Progression; Female; Lens, Crystalline; Male; Mice; Mice, Inbred Strains; Pantetheine; Ultraviolet Rays | 2000 |
Contribution of dithiol ligands to in vitro and in vivo trypanocidal activities of dithiaarsanes and investigation of ligand exchange in an aqueous solution.
Topics: Animals; Arsenicals; Cysteamine; Dansyl Compounds; Disease Models, Animal; Female; Mice; Parasitic Sensitivity Tests; Structure-Activity Relationship; Sulfhydryl Compounds; Thioctic Acid; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosomiasis, African | 2000 |
Pharmacological properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-.
Topics: Animals; Anti-Ulcer Agents; Aspirin; Cysteamine; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethanol; Gastric Acid; Gastric Mucosa; H(+)-K(+)-Exchanging ATPase; Indomethacin; Omeprazole; Perfusion; Proton Pump Inhibitors; Pyrroles; Quinolines; Rats; Rats, Sprague-Dawley; Sodium Hydroxide; Stomach; Stomach Ulcer; Time Factors | 2001 |
Gastric antisecretory and antiulcer activity of oxytocin in rats and guinea pigs.
Topics: Acetic Acid; Acute Disease; Animals; Anti-Ulcer Agents; Chronic Disease; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Ethanol; Female; Gastric Acid; Gastric Mucosa; Guinea Pigs; Histamine; Indomethacin; Male; Oxytocin; Pylorus; Ranitidine; Rats; Rats, Wistar; Stomach; Stomach Ulcer; Vasotocin | 2001 |
Pathogenesis of duodenal ulceration produced by cysteamine or propionitrile: influence of vagotomy, sympathectomy, histamine depletion, H-2 receptor antagonists and hormones.
Topics: Adrenalectomy; Animals; Castration; Cimetidine; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Gastric Juice; Guanidines; Histamine; Histamine H2 Antagonists; Hypophysectomy; Metiamide; Nitriles; Rats; Sympathectomy; Thiourea; Thyroidectomy; Vagotomy | 1979 |
Duodenal ulcer disease. Animal model: cysteamine-induced acute and chronic duodenal ulcer in the rat.
Topics: Acute Disease; Animals; Chronic Disease; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Female; Gastric Juice; Gastrins; Male; Rats | 1978 |
Selective inhibition of duodenal and jejunal villous cell alkaline phosphatase by the duodenal ulcerogen cysteamine.
Topics: Alkaline Phosphatase; Animals; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Female; In Vitro Techniques; Injections, Subcutaneous; Jejunum; Kidney; Liver; Microvilli; Organ Specificity; Rats; Rats, Inbred Strains | 1991 |
Comparison of efficacy of cysteamine in depleting prolactin immunoreactivity in different hyperprolactinemic animal models.
Topics: Analysis of Variance; Animals; Cysteamine; Disease Models, Animal; Female; Hyperprolactinemia; Paraneoplastic Endocrine Syndromes; Pituitary Gland; Pituitary Neoplasms; Prolactin; Rats; Rats, Inbred ACI; Rats, Inbred BUF; Rats, Inbred WF | 1991 |
Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Avoidance Learning; Cerebral Cortex; Choline O-Acetyltransferase; Corticotropin-Releasing Hormone; Cysteamine; Disease Models, Animal; Dopamine; Hydroxydopamines; Ibotenic Acid; Male; Norepinephrine; Oxidopamine; Physostigmine; Rats; Rats, Inbred Strains; Reference Values; Serotonin; Somatostatin | 1990 |
[The site (central or peripheral) of the anti-ulcer action of dalargin, a synthetic analog of endogenous opioids in an experimental model of cysteamine-induced duodenal ulcer in rats].
Topics: Animals; Anti-Ulcer Agents; Brain; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Injections, Intraventricular; Injections, Subcutaneous; Male; Rats; Rats, Inbred Strains; Receptors, Opioid | 1987 |
[Zinc sulfate in various models of acute experimental ulcer].
Topics: Acids; Acute Disease; Animals; Cysteamine; Disease Models, Animal; Pepsin A; Peptic Ulcer; Rats; Rats, Inbred Strains; Stress, Physiological; Sulfates; Zinc; Zinc Sulfate | 1986 |
Development of cysteamine-induced ultrastructural surface changes on duodenal mucosa.
Topics: Animals; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Female; Intestinal Mucosa; Microscopy, Electron, Scanning; Microvilli; Rats; Rats, Inbred Strains | 1987 |
Cysteamine induces duodenal ulcer in the mouse.
Topics: Administration, Oral; Animals; Cysteamine; Disease Models, Animal; Drug Administration Schedule; Duodenal Ulcer; Female; Gastric Juice; Injections, Subcutaneous; Mice | 1986 |
[The effect of secretin on the cysteamine induced inhibition of alkaline secretion by the duodenal mucosa].
Topics: Animals; Bicarbonates; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Intestinal Mucosa; Male; Rats; Rats, Inbred Strains; Secretin | 1986 |
Augmentation of cysteamine and mepirizole-induced lesions in the rat duodenum and stomach by histamine or indomethacin.
Topics: Animals; Cysteamine; Disease Models, Animal; Drug Synergism; Duodenal Ulcer; Epirizole; Histamine; Indomethacin; Male; Pyrazoles; Rats; Stomach Ulcer | 1986 |
[Experimental production of various types of cholestasis and the effect of cysteamine].
Topics: Animals; Cholestasis; Cholestasis, Intrahepatic; Cysteamine; Disease Models, Animal; Male; Rats; Rats, Inbred Strains | 1986 |
Biliary and pancreatic secretions influence experimental duodenal ulcer without affecting gastric secretion in the rat.
Topics: Animals; Bile; Common Bile Duct; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Female; Gastric Acid; Gastric Juice; Ligation; Pancreatic Juice; Pepsin A; Pylorus; Rats; Rats, Inbred Strains; Taurocholic Acid | 1985 |
Healing of cysteamine-induced duodenal ulcers in the rat.
Topics: Animals; Brunner Glands; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Duodenum; Epithelium; Female; Intestinal Mucosa; Rats; Rats, Inbred Strains; Regeneration; Time Factors | 1985 |
[Adenylate cyclase activity of the gastric mucosa and the morphological changes in the gastrointestinal tract in the experimental reproduction of duodenal ulcers with subsequent truncal vagotomy].
Topics: Adenylyl Cyclases; Animals; Cysteamine; Digestive System; Disease Models, Animal; Duodenal Ulcer; Gastric Mucosa; Histocytochemistry; Male; Rats; Vagotomy | 1985 |
Cysteamine-induced duodenal ulcers: a new model to test antiulcer agents.
Topics: Adrenocorticotropic Hormone; Animals; Antacids; Cysteamine; Desoxycorticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Duodenal Ulcer; Fasting; Female; Gastric Juice; Ligation; Male; Prednisolone; Prostaglandins; Pylorus; Rats; Scopolamine Derivatives; Secretory Rate; Sex Factors; Stimulation, Chemical; Time Factors | 1974 |
Experimental model for production of perforating duodenal ulcers by cysteamine in the rat.
Topics: Administration, Oral; Animals; Cysteamine; Disease Models, Animal; Duodenal Ulcer; Female; Injections, Subcutaneous; Peptic Ulcer Perforation; Rats | 1973 |